Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | DGKG | P49619 | 1/20 | 0.34 |
| ▸ | DGKB | Q9Y6T7 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806740 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2 | |
| SCHEMBL6358740 | 0.82 | RAB9A (0.42) | RAB9APAX8MGLLKMT2AMEN1 | |
| SCHEMBL7100099 | 0.74 | RAB9A (0.36) | RAB9APAX8MGLLKMT2AMEN1 | |
| SCHEMBL6442004 | 0.68 | SMN1; SMN2 (0.78) | SMN1; SMN2KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL6810794 | 0.67 | PDE5A (0.31) | — | |
| SCHEMBL6629463 | 0.66 | SMN1; SMN2 (0.49) | SMN1; SMN2OPRD1ALDH1A1 | |
| SCHEMBL6202269 | 0.65 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL4496552 | 0.65 | RIPK2 (0.47) | RAB9ASMN1; SMN2KMT2AOPRD1CCR5 | |
| SCHEMBL6916828 | 0.65 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL28038421 | 0.65 | SMN1; SMN2 (0.60) | SMN1; SMN2KMT2AMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064990-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | RAB9A 815/4885PAX8 4601/4885SMN1; SMN2 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.